Lyell Immunopharma, Inc. - Common Stock (LYEL) is currently showing a slightly bullish headline tone with a mixed / range backdrop. The latest news flow is being framed here as context rather than prediction, so beginners can quickly see whether headlines are helping, hurting, or complicating the chart story. Earnings tone is currently no clear earnings read.
HEADLINE TAKE: There is a mild positive lean in the higher-value headlines, though the setup is not strong enough to call decisively bullish.
Change stock
Search another ticker to view its latest news page.
SOUTH SAN FRANCISCO, Calif., June 25, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today announced that members of its senior management team will participate in a fireside chat at the H.C.
Article excerpt provided by the FMP news feed. AI is used only for the optional "Why this matters" read.Read full article ↗
seekingalpha.com13 Jun 2026
Lyell Immunopharma: Undervalued Ahead Of A Major CAR-T Inflection
Lyell Immunopharma (LYLE) offers asymmetric upside, with ronde-cel showing best-in-class durability and safety in relapsed/refractory LBCL. LYLE trades near cash value, with the market heavily discounting its pipeline despite advanced pivotal trials and strong early efficacy signals. Ronde-cel's dual CD19/CD20 targeting and CD62L+ enrichment underpin durable responses, low severe toxicity, and potential for outpatient administration.
Article excerpt provided by the FMP news feed. AI is used only for the optional "Why this matters" read.Read full article ↗
globenewswire.com12 Jun 2026
Lyell Immunopharma Presents Updated Safety Data and Translational Insights for Rondecabtagene Autoleucel (Ronde-Cel) in Patients with Large B-Cell Lymphoma at European Hematology Association 2026 Congress
More than 100 patients treated with ronde-cel in 2L and 3L+ LBCL, with a manufacturing success rate of 97% No Grade ≥ 3 CRS and low rates of Grade ≥ 3 ICANS, supporting outpatient administration Translational data support biological basis for durable responses, including enhanced memory potential of cytotoxic effector cells from CD62L+ enrichment, and CD19/CD20 dual-targeting to overcome low antigen expression PiNACLE pivotal clinical trial in 3L+ setting data update expected in second half of 2026; pivotal data re…
Article excerpt provided by the FMP news feed. AI is used only for the optional "Why this matters" read.Read full article ↗
Older updates drop into a lighter feed
seekingalpha.com
10 Jun 2026
Lyell Immunopharma, Inc. (LYEL) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Lyell Immunopharma Provides Update on Safety Profile of LYL273 in Relapsed or Refractory Metastatic Colorectal Cancer and Amends Phase 1 Trial to Phase 1/2 Expansion
Lyell Immunopharma to Present Phase 1/2 Safety and Translational Data for Ronde-Cel in Large B-Cell Lymphoma at the European Hematology Association 2026 Congress
